ATE457998T1 - Abgeschwächte mikroorganismen für die behandlung von infektionen - Google Patents

Abgeschwächte mikroorganismen für die behandlung von infektionen

Info

Publication number
ATE457998T1
ATE457998T1 AT06012488T AT06012488T ATE457998T1 AT E457998 T1 ATE457998 T1 AT E457998T1 AT 06012488 T AT06012488 T AT 06012488T AT 06012488 T AT06012488 T AT 06012488T AT E457998 T1 ATE457998 T1 AT E457998T1
Authority
AT
Austria
Prior art keywords
infections
treatment
attenuated microorganisms
attenuated
microorganisms
Prior art date
Application number
AT06012488T
Other languages
English (en)
Inventor
Gordon Dougan
Joseph David Santangelo
David William Holden
Jacqueline Elizabeth Shea
Zoe Hindle
Original Assignee
Microscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microscience Ltd filed Critical Microscience Ltd
Application granted granted Critical
Publication of ATE457998T1 publication Critical patent/ATE457998T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06012488T 1999-05-10 2000-05-09 Abgeschwächte mikroorganismen für die behandlung von infektionen ATE457998T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9910812.8A GB9910812D0 (en) 1999-05-10 1999-05-10 Vaccine composition

Publications (1)

Publication Number Publication Date
ATE457998T1 true ATE457998T1 (de) 2010-03-15

Family

ID=10853168

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00927538T ATE346090T1 (de) 1999-05-10 2000-05-09 Abgeschwaechte mikroorganismen fuer die behandlung von infektionen
AT06012488T ATE457998T1 (de) 1999-05-10 2000-05-09 Abgeschwächte mikroorganismen für die behandlung von infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00927538T ATE346090T1 (de) 1999-05-10 2000-05-09 Abgeschwaechte mikroorganismen fuer die behandlung von infektionen

Country Status (28)

Country Link
US (3) US6756042B1 (de)
EP (2) EP1702927B1 (de)
JP (1) JP4583607B2 (de)
KR (2) KR100811319B1 (de)
CN (1) CN1177863C (de)
AP (1) AP1470A (de)
AT (2) ATE346090T1 (de)
AU (1) AU763898B2 (de)
BR (1) BRPI0010418B8 (de)
CA (1) CA2372553C (de)
CY (1) CY1107656T1 (de)
CZ (1) CZ301926B6 (de)
DE (2) DE60043868D1 (de)
DK (1) DK1183269T3 (de)
EA (1) EA004921B1 (de)
ES (1) ES2277591T3 (de)
GB (1) GB9910812D0 (de)
HU (1) HUP0201117A3 (de)
IL (3) IL146255A0 (de)
MA (1) MA25411A1 (de)
MX (1) MXPA01011477A (de)
NO (1) NO329520B1 (de)
NZ (1) NZ539260A (de)
OA (1) OA11940A (de)
PT (1) PT1183269E (de)
TR (1) TR200702949T2 (de)
WO (1) WO2000068261A2 (de)
ZA (1) ZA200108912B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG119177A1 (en) * 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
ATE403728T1 (de) * 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0105924D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Promoter
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008153772A2 (en) * 2007-05-25 2008-12-18 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
RU2392003C2 (ru) * 2008-04-02 2010-06-20 ФГОУ ВПО Курская государственная сельскохозяйственная академия им. профессора И.И. Иванова Способ получения сальмонеллезной вакцины
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
EP3613430A2 (de) 2013-10-11 2020-02-26 Servizo Galego De Saúde (Sergas) Abgeschwächte lebendimpfstoffe
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP3922255A1 (de) 2020-06-10 2021-12-15 Prokarium Limited Krebstherapie
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
EP4124342A1 (de) 2021-07-28 2023-02-01 Prokarium Limited Krebstherapie mit lebenden attenuierten bakterien
WO2023105076A1 (en) 2021-12-09 2023-06-15 Prokarium Limited Combination cancer therapy
AU2023346467A1 (en) 2022-09-21 2025-03-27 Prokarium Limited Salmonella strain with chromosomally integrated landing pad
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) * 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4810648A (en) * 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5397697A (en) * 1989-01-10 1995-03-14 Ciba-Geigy Corporation Identification of plant-responsive genes of bacteria
FR2664614B1 (fr) 1990-07-11 1992-10-16 Pasteur Institut Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires.
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
AU2509592A (en) 1991-08-22 1993-03-16 Washington University Polynucleotide probes for salmonella
AU2778992A (en) * 1991-10-07 1993-05-03 Idaho Research Foundation Inc., The Genetic construct for selection of homologous recombinants on a single selective medium
AU3130893A (en) 1991-11-15 1993-06-15 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
WO1994011024A1 (en) 1992-11-06 1994-05-26 Regents Of The University Of Minnesota Composition protective against p. multocida pasteurellosis infection
WO1994026933A1 (en) 1993-05-13 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection
AU3958895A (en) 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
SG119177A1 (en) * 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
US5700683A (en) * 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
AU7738396A (en) 1995-11-14 1997-06-05 General Hospital Corporation, The Salmonella secreted proteins and uses thereof
US6030624A (en) 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1998035562A1 (en) 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
GB9804809D0 (en) 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
ATE403728T1 (de) * 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
BR9915165A (pt) * 1998-11-09 2001-12-04 Microscience Ltd Genes e proteìnas de virulência e uso dos mesmos
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
EP1226254A2 (de) 1999-11-05 2002-07-31 L'Unité de Recherche en Biologie Moléculaire (URBM) des Facultés Universitaires Notre Dame de la Paix (FUNDP) Virulenzgene, proteine, und ihre verwendung
JP3414342B2 (ja) * 1999-11-25 2003-06-09 日本電気株式会社 集積回路チップの実装構造および実装方法
JP2003520034A (ja) * 1999-12-23 2003-07-02 ヴィマックス リミテッド ビルレンス遺伝子、タンパク質、およびそれらの用途
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria

Also Published As

Publication number Publication date
HUP0201117A2 (en) 2002-08-28
MXPA01011477A (es) 2002-06-04
ZA200108912B (en) 2002-12-24
NZ539260A (en) 2007-01-26
NO20015464D0 (no) 2001-11-08
WO2000068261A2 (en) 2000-11-16
US7887816B2 (en) 2011-02-15
US6756042B1 (en) 2004-06-29
CN1177863C (zh) 2004-12-01
AP2001002317A0 (en) 2001-12-31
DK1183269T3 (da) 2007-04-02
EP1702927A1 (de) 2006-09-20
ATE346090T1 (de) 2006-12-15
GB9910812D0 (en) 1999-07-07
CY1107656T1 (el) 2013-04-18
WO2000068261A3 (en) 2001-02-08
DE60043868D1 (de) 2010-04-01
PT1183269E (pt) 2007-02-28
EA004921B1 (ru) 2004-10-28
DE60031974T2 (de) 2007-03-15
ES2277591T3 (es) 2007-07-16
AU4593200A (en) 2000-11-21
KR100680391B1 (ko) 2007-02-08
AP1470A (en) 2005-09-26
CA2372553A1 (en) 2000-11-16
PL354355A1 (en) 2004-01-12
NO329520B1 (no) 2010-11-01
KR20020018193A (ko) 2002-03-07
OA11940A (en) 2006-04-12
EP1702927B1 (de) 2010-02-17
IL146255A0 (en) 2002-07-25
EA200101187A1 (ru) 2002-04-25
BRPI0010418B8 (pt) 2021-05-25
BR0010418B1 (pt) 2013-04-16
JP4583607B2 (ja) 2010-11-17
IL146255A (en) 2008-11-26
US7211264B2 (en) 2007-05-01
CA2372553C (en) 2011-09-27
DE60031974D1 (de) 2007-01-04
CZ301926B6 (cs) 2010-08-04
TR200702949T2 (tr) 2007-08-21
US20040191866A1 (en) 2004-09-30
MA25411A1 (fr) 2002-04-01
KR100811319B1 (ko) 2008-03-07
CZ20014030A3 (cs) 2002-06-12
IL186993A (en) 2010-02-17
AU763898B2 (en) 2003-07-31
CN1360594A (zh) 2002-07-24
KR20060101563A (ko) 2006-09-25
US20080274139A1 (en) 2008-11-06
NO20015464L (no) 2001-11-08
HUP0201117A3 (en) 2004-01-28
BR0010418A (pt) 2003-07-22
EP1183269A1 (de) 2002-03-06
JP2003509008A (ja) 2003-03-11
EP1183269B1 (de) 2006-11-22

Similar Documents

Publication Publication Date Title
DE60043868D1 (de) Abgeschwächte Mikroorganismen für die Behandlung von Infektionen
ATE305307T1 (de) Reboxetin zur behandlung von migränekopfschmerzen
DE69528109D1 (de) Thieno -1,5- benzodiazepin zur Behandlung gastrointestinaler Beschwerden
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60024649D1 (de) Verbindungen für die behandlung von ischämie
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60001421D1 (de) Behandlung von abgas
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
NO20014314D0 (no) Blandinger og metoder for behandling av stafylokokkisk infeksjon
EP1117431A4 (de) Behandlung von acidose
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
NO20022949D0 (no) Attenuerte mikroorganismer for behandling av infeksjon
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
DE60006363D1 (de) Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes
DE50209798D1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne
EP1484066A4 (de) Mittel zur behandlung von infektionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties